Kilitch Drugs (India) Ltd

NSE
KILITCH •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Kilitch Drugs (India) Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
216.60% Gain from 52W Low
22.9
TTM PE Ratio
Below industry Median
43.7
Price to Book Ratio
Above industry Median
4.2
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is less than 1
0.9
RSI
RSI is mid-range
45
MFI
MFI is mid-range
44.1

Kilitch Drugs (India) Ltd Key Financials

*All values are in ₹ Cr.

Kilitch Drugs (India) Ltd shareholding Pattern

Promoter
69.2%
Public
30.8%

Kilitch Drugs (India) Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
7
Bearish Moving Averages
9
5Day EMA
400.60
10Day EMA
408.50
12Day EMA
410.30
20Day EMA
412.00
26Day EMA
410.00
50Day EMA
392.70
100Day EMA
352.60
200Day EMA
298.30
Delivery & Volume
Resistance & Support
390.28
Pivot
Resistance
First Resistance
412.37
Second Resistance
428.98
Third Resistance
451.07
Support
First Support
373.67
Second support
351.58
Third Support
334.97
Relative Strength Index
44.97
Money Flow Index
44.14
MACD
0.31
MACD Signal
7
Average True Range
22.62
Average Directional Index
24.35
Rate of Change (21)
3.90
Rate of Change (125)
112.26

Kilitch Drugs (India) Ltd Company background

Founded in: 1992
Managing director: Mukund P Mehta
Kilitch Drugs (India) Limited (KDIL) was incorporated in May, 1992 as a public limited company. The Company is a pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions.The Company went public in Feb.94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules,liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.95 to expand the injectible capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions O T C and ethical.A Pharmaceutical formulation plant at Sanaa Republic of Yemen was set up at a cost of Rs 15 crore by entering into an agreement with AlFath Trading Corporation.It also entered into an agreement with a Miami company for the export of their medicine to West Indies, south and central America.The company entered into a contract with one of the leading company in the Republic of Yemen which it had set up at a cost of Rs 2.5cr tanning unit, which was implemented in the year 199596. The company had set up a bulk drug unit at Patalganga, Maharashtra for producing raw materials for formulations. The company exports to Sudan, Yemen, middleeast, Miami and certain south American companies. KDIL started marketing a range of injectables from the factory on ethical basis. The company also introduced a new product clueplus, BonBon Gripe Water and Kilitch Balm.The Company launched a new product BENIN in the market in 2011. During the year 201112, the Company sold its business located at Paonta Sahib, Himachal Pradesh as a going concern on a slump sale basis along with transfer of services set forth in the Business Transfer Agreement (BTA). The undertaking was sold and transferred on 28th February 2012 after getting all the necessary clearances as indicated in the BTA. It retained its Name, Trademark (Kilitch) and all other properties and assets at Mumbai. It transferred certain products by entering into a Product Transfer Agreement (PTA) with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.
Read More

Kilitch Drugs (India) Ltd FAQs

Kilitch Drugs (India) Ltd shares are currently priced at 395.75 on NSE and 394.95 on BSE as of 2/21/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Kilitch Drugs (India) Ltd [KILITCH] share was 178.79. The Kilitch Drugs (India) Ltd [KILITCH] share hit a 1-year low of Rs. 125 and a 1-year high of Rs. 470.

The market cap of Kilitch Drugs (India) Ltd is Rs. 636.46 Cr. as of 2/21/2024 12:00:00 AM.

The PE ratios of Kilitch Drugs (India) Ltd is 33.33 as of 2/21/2024 12:00:00 AM.

The PB ratios of Kilitch Drugs (India) Ltd is 3 as of 2/21/2024 12:00:00 AM

You can easily buy Kilitch Drugs (India) Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage